July 28, 2015


Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer

  • Boehringer Ingelheim expands its strong position in lung cancer obtaining exclusive rights to HM61713, a 3rd generation EGFR targeting agent
  • This new partnership will aim to achieve first market authorisation for HM61713 for patients with EGFR mutation-positive NSCLC by 2017 in the U.S.
  • Expands Boehringer Ingelheim’s broad commitment to cancer and specifically the development of innovative targeted therapies in lung cancer

Boehringer Ingelheim and Hanmi Pharmaceutical Co. Ltd today"...

Continue Reading >

July 28, 2015


cippe 2015 Shanghai: Focus on Innovation and Upgrade of Global Petrochemical Industry and Market Trends

In the coming five years, China's economy will see significant changes in many aspects, with the economic growth rate from high to moderate, the growth pattern from extensive growth in scale and speed to intensive growth in quality and efficiency, its driving force from investment to innovation, and the structure from capacity expansion-oriented to expansion-and-optimization-oriented. Focusing on the upgrade of the traditional petrochemical industry, the challenges faced by the industry and the development trends of the petrochemical"...

Continue Reading >

July 27, 2015


Vertical Progress Trading Company to be Exclusive Distributor of Obagi Medical Products in the United Arab Emirates

Cellogique Corporation is pleased to announce their newly established partnership with Vertical Progress Trading Company. Cellogique Corporation has granted Vertical Progress Trading Company exclusive distribution of Obagi Medical Products, a division of Valeant Pharmaceuticals.

The Vertical Progress team notes, “Obagi is a world-renowned brand providing an extensive"...

Continue Reading >

July 27, 2015


Cancer Experts to Gather In Dubai in October

More than 1,200 Oncologists and Allied healthcare professionals will gather in Dubai this year from 29 to 31 October for the UAE Cancer Congress to learn and network with Cancer Specialists from around the globe. The participants will discuss the latest cancer research, guidelines, developments and showcase best practices from regional and international institutions viz, MD Anderson USA, Tata Memorial Hospital and other leading institutions from India, Korea, Singapore, Australia etc.


Continue Reading >

July 27, 2015


European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment to ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. The EMA awards an accelerated assessment to those medicines deemed to be of major public health interest and, in particular, therapeutic innovation.


Continue Reading >

July 20, 2015


Algeria to partake in international conference on fight against Ebola Tuesday, Wednesday in Malabo

Algeria will participate in the international conference on Africa's fight against Ebola, scheduled for Tuesday and Wednesday in Malabo (Equatorial Guinea) and will be represented by Minister of Health, Population and Hospital Reform Abdelmalek Boudiaf.

"Mr Boudiaf was designated by President of the Republic Abdelaziz Bouteflika, to participate Tuesday in the ministerial"...

Continue Reading >

July 16, 2015


Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)

  • New guidance recommends OFEV® (nintedanib*) for the treatment of IPF
  • This recommendation puts a high value on the potential benefit of OFEV® on patient-important outcomes such as disease progression as measured by rate of FVC decline and mortality

Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline which suggests that clinicians use OFEV® (nintedanib*)"...

Continue Reading >

July 15, 2015


Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that a New Drug Application (NDA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.

The NDA submission was based on the pivotal Phase 3"...

Continue Reading >

July 14, 2015


Scarcity in AVLOCADYL drug in pharmacies raise panic among heart patients

Different pharmacies at the national territory noticed, since weeks, a dangerous scarcity in chronic diseases drugs, especially the "AVLOCARDYL", which concerned an important category of society including the heart patients, who complained since a quiet of time from the lack of medicines in pharmacies and scarcity of drugs, at a time when most of them were forced to resort to their relatives who live abroad to bring them the drug that is considered necessary for the prevention of sudden and dangerous heart attacks.


Continue Reading >

July 5, 2015


GCC and German Rheumatologists to establish “Spondyloarthritis” Center of Excellence in partnership with Abbvie pharmaceuticals

  • Spondyloarthritis disease (SpA), is a type of inflammatory back pain often mistaken for mechanical back pain, that affects approximately 3% of adults
  • Studies show gap between onset of disease and diagnosis reach up to nine years

In partnership with AbbVie Biopharmaceuticals, a global, research-based biopharmaceutical company, Rheumatologists from around the GCC journeyed to Charite Berlin University Hospital in Germany to discuss the recent updates in the management of Spondyloarthritis disease (SpA),"...

Continue Reading >

Forex Market Video